# TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

> **NCT01455389** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genprex, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** DOTAP:Chol-TUSC2
- **DRUG:** Erlotinib
- **DRUG:** Dexamethasone
- **DRUG:** Diphenhydramine

## Key facts

- **NCT ID:** NCT01455389
- **Lead sponsor:** Genprex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2016-10-27
- **Final completion:** 2020-09-28
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Trial terminated by sponsor after decision to evaluate combination of quaratusugene ozeplasmid and osimertinib instead of further evaluating quaratusugene ozeplasmid and erlotinib.
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01455389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01455389, "TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01455389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*